|
Alibaba Health Information Technology Limited (0241.HK) DCF -Bewertung
HK | Healthcare | Medical - Pharmaceuticals | HKSE
|
- ✓ Fully Editable: Tailor To Your Needs In Excel Or Sheets
- ✓ Professional Design: Trusted, Industry-Standard Templates
- ✓ Pre-Built For Quick And Efficient Use
- ✓ No Expertise Is Needed; Easy To Follow
Alibaba Health Information Technology Limited (0241.HK) Bundle
Als Investor oder Analyst dient der DCF-Taschenrechner von Alibaba Health Information Technology Limited (0241HK) für eine genaue Bewertung. Mit echten Daten von Alibaba Health Information Technology Limited sind Sie problemlos Prognosen anpassen und die Auswirkungen in Echtzeit beobachten.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 10,254.8 | 16,583.1 | 21,989.3 | 28,599.1 | 28,880.7 | 37,931.5 | 49,818.7 | 65,431.2 | 85,936.5 | 112,867.8 |
| Revenue Growth, % | 0 | 61.71 | 32.6 | 30.06 | 0.98471 | 31.34 | 31.34 | 31.34 | 31.34 | 31.34 |
| EBITDA | -56.7 | 55.7 | -201.0 | -26.2 | 1,067.6 | 187.7 | 246.5 | 323.8 | 425.3 | 558.5 |
| EBITDA, % | -0.55259 | 0.33597 | -0.91421 | -0.0914583 | 3.7 | 0.49485 | 0.49485 | 0.49485 | 0.49485 | 0.49485 |
| Depreciation | 44.5 | 42.3 | 64.7 | 68.1 | 57.4 | 107.8 | 141.6 | 185.9 | 244.2 | 320.7 |
| Depreciation, % | 0.43442 | 0.25535 | 0.29438 | 0.23809 | 0.19863 | 0.28417 | 0.28417 | 0.28417 | 0.28417 | 0.28417 |
| EBIT | -101.2 | 13.4 | -265.8 | -94.2 | 1,010.2 | 79.9 | 105.0 | 137.9 | 181.1 | 237.8 |
| EBIT, % | -0.98701 | 0.08062007 | -1.21 | -0.32954 | 3.5 | 0.21068 | 0.21068 | 0.21068 | 0.21068 | 0.21068 |
| Total Cash | 3,203.1 | 12,435.1 | 11,271.5 | 11,666.1 | 10,208.5 | 17,723.1 | 23,277.3 | 30,572.0 | 40,152.9 | 52,736.2 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | 346.8 | 335.1 | 551.4 | 618.5 | 839.0 | 984.5 | 1,293.1 | 1,698.3 | 2,230.6 | 2,929.6 |
| Account Receivables, % | 3.38 | 2.02 | 2.51 | 2.16 | 2.91 | 2.6 | 2.6 | 2.6 | 2.6 | 2.6 |
| Inventories | 1,300.8 | 1,569.4 | 1,656.5 | 2,246.5 | 1,495.8 | 3,240.5 | 4,256.1 | 5,589.9 | 7,341.7 | 9,642.4 |
| Inventories, % | 12.68 | 9.46 | 7.53 | 7.86 | 5.18 | 8.54 | 8.54 | 8.54 | 8.54 | 8.54 |
| Accounts Payable | 1,993.5 | 2,726.6 | 3,770.7 | 3,968.8 | 3,580.4 | 6,016.3 | 7,901.7 | 10,378.0 | 13,630.3 | 17,901.8 |
| Accounts Payable, % | 19.44 | 16.44 | 17.15 | 13.88 | 12.4 | 15.86 | 15.86 | 15.86 | 15.86 | 15.86 |
| Capital Expenditure | -8.1 | -18.2 | -16.0 | -6.0 | -24.3 | -27.8 | -36.5 | -48.0 | -63.0 | -82.8 |
| Capital Expenditure, % | -0.07885186 | -0.11004 | -0.07255457 | -0.02096924 | -0.08428747 | -0.07334124 | -0.07334124 | -0.07334124 | -0.07334124 | -0.07334124 |
| Tax Rate, % | 5.95 | 5.95 | 5.95 | 5.95 | 5.95 | 5.95 | 5.95 | 5.95 | 5.95 | 5.95 |
| EBITAT | 73.3 | 11.6 | -279.5 | -91.6 | 950.1 | 60.4 | 79.4 | 104.3 | 136.9 | 179.8 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | 455.7 | 511.9 | 510.0 | -488.5 | 1,125.0 | 685.9 | 745.7 | 979.4 | 1,286.4 | 1,689.5 |
| WACC, % | 9.43 | 9.44 | 9.44 | 9.44 | 9.44 | 9.43 | 9.43 | 9.43 | 9.43 | 9.43 |
| PV UFCF | ||||||||||
| SUM PV UFCF | 3,970.2 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | 1,723 | |||||||||
| Terminal Value | 23,181 | |||||||||
| Present Terminal Value | 14,769 | |||||||||
| Enterprise Value | 18,740 | |||||||||
| Net Debt | -10,121 | |||||||||
| Equity Value | 28,860 | |||||||||
| Diluted Shares Outstanding, MM | 14,091 | |||||||||
| Equity Value Per Share | 2.05 |
What You Will Receive
- Genuine Alibaba Data: Preloaded financial information – covering everything from revenue to EBIT – based on actual and projected figures.
- Comprehensive Customization: Modify all key parameters (yellow cells) such as WACC, growth %, and tax rates.
- Immediate Valuation Adjustments: Automatic recalculations to assess how changes affect Alibaba’s fair value.
- Flexible Excel Template: Designed for quick modifications, scenario analysis, and detailed forecasting.
- Efficient and Precise: Avoid the hassle of creating models from scratch while ensuring accuracy and adaptability.
Key Features
- Comprehensive Alibaba Financials: Gain access to reliable pre-loaded historical data and future forecasts for Alibaba Health Information Technology Limited (0241HK).
- Tailorable Forecast Assumptions: Modify highlighted cells to adjust parameters such as WACC, growth rates, and profit margins.
- Automated Calculations: Enjoy real-time updates on DCF, Net Present Value (NPV), and cash flow analyses.
- Interactive Dashboard: Utilize user-friendly charts and summaries to clearly visualize your valuation outcomes.
- Designed for All Skill Levels: An intuitive layout suitable for investors, CFOs, and consultants, whether novices or experts.
How It Works
- Download: Obtain the pre-configured Excel spreadsheet containing Alibaba Health Information Technology Limited (0241HK) financial data.
- Customize: Modify projections such as revenue growth, EBITDA percentage, and WACC to suit your analysis.
- Update Automatically: Watch as the intrinsic value and NPV calculations refresh in real-time.
- Test Scenarios: Generate various projections and instantly compare their potential outcomes.
- Make Decisions: Leverage the valuation insights to inform your investment approach.
Why Opt for This Calculator for Alibaba Health Information Technology Limited (0241HK)?
- Precise Financials: Utilize accurate Alibaba Health data for trustworthy valuation outcomes.
- Tailorable Options: Modify essential inputs such as growth rates, WACC, and tax rates to align with your forecasts.
- Efficiency Boost: Built-in calculations save you the hassle of starting from square one.
- Professional-Quality Tool: Ideal for investors, analysts, and consulting professionals.
- Easy to Navigate: User-friendly design with clear, step-by-step guidance for all users.
Who Can Benefit from This Product?
- Professional Investors: Develop precise and dependable valuation models for portfolio assessment.
- Corporate Finance Teams: Evaluate valuation scenarios to inform and enhance internal strategies.
- Consultants and Advisors: Deliver clients with accurate valuation insights specifically for Alibaba Health Information Technology Limited (0241HK).
- Students and Educators: Utilize real-world data for practicing and teaching financial modeling techniques.
- Tech Enthusiasts: Gain insight into how technology companies like Alibaba Health are assessed in the financial market.
Contents of the Template
- Operating and Balance Sheet Data: Pre-filled historical data and forecasts for Alibaba Health Information Technology Limited (0241HK), including revenue, EBITDA, EBIT, and capital expenditures.
- WACC Calculation: A dedicated sheet for Weighted Average Cost of Capital (WACC), featuring parameters such as Beta, risk-free rate, and share price.
- DCF Valuation (Unlevered and Levered): Customizable Discounted Cash Flow models to determine intrinsic value, complete with detailed calculations.
- Financial Statements: Pre-loaded annual and quarterly financial statements to facilitate comprehensive analysis.
- Key Ratios: Provides profitability, leverage, and efficiency ratios specific to Alibaba Health Information Technology Limited (0241HK).
- Dashboard and Charts: Visual summary of valuation outputs and assumptions for straightforward analysis of results.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.